Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;23(11):e460-e461.
doi: 10.1016/S1473-3099(23)00575-3. Epub 2023 Sep 18.

Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant

Keiya Uriu  1 , Jumpei Ito  2 , Yusuke Kosugi  1 , Yuri L Tanaka  3 , Yuka Mugita  4 , Ziyi Guo  5 , Alfredo A Hinay Jr  5 , Olivia Putri  6 , Yoonjin Kim  7 , Ryo Shimizu  4 , Mst Monira Begum  4 , Michael Jonathan  4 ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Akatsuki Saito  8 , Terumasa Ikeda  4 , Kei Sato  9
Affiliations

Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant

Keiya Uriu et al. Lancet Infect Dis. 2023 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This work was supported in part by the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA programme (JP223fa627001 to KS); AMED SCARDA Program on R&D of New Generation Vaccine Including New Modality Application (JP223fa727002 to KS); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146 to KS; JP21fk0108494 to G2P-Japan Consortium, TI, and KS; JP21fk0108425 to KS; JP21fk0108432 to KS; JP22fk0108511 to G2P-Japan Consortium, AS, TI, and KS; JP22fk0108516 to KS; JP22fk0108506 to AS and KS; JP22fk0108534 to TI and KS); AMED Research Program on HIV/AIDS (JP23fk0410047 to AS; JP23fk0410056 to AS; JP23fk0410058 to AS; JP22fk0410055 to TI; JP22fk0410039 to KS); JST PRESTO (JPMJPR22R1 to JI); JST CREST (JPMJCR20H4 to KS); JSPS KAKENHI Grant-in-Aid for Scientific Research C (22K07103 to TI); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (23K14526 to JI); JSPS Leading Initiative for Excellent Young Researchers (LEADER; to TI); JSPS Core-to-Core Program (A. Advanced Research Networks; JPJSCCA20190008 to KS); JSPS Research Fellow DC2 (22J11578 to KU); JSPS Research Fellow DC1 (23KJ0710 to YKo); The Tokyo Biochemical Research Foundation (to KS); The Mitsubishi Foundation (to KS); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to TI); The Naito Foundation (to TI); International Joint Research Project of the Institute of Medical Science, the University of Tokyo (to TI and AS). JI has received consulting fees and honoraria for lectures from Takeda Pharmaceutical. KS has received consulting fees from Moderna Japan and Takeda Pharmaceutical and honoraria for lectures from Gilead Sciences, Moderna Japan, and Shionogi & Co. All other authors declare no competing interests. KU and JI contributed equally to this study. Members of The Genotype to Phenotype Japan (G2P-Japan) Consortium are listed in the appendix (p 12).

Publication types

LinkOut - more resources